AR095152A1 - SOLID PHARMACEUTICAL COMPOSITION FOR AGOMELATINE BUCAL ADMINISTRATION - Google Patents

SOLID PHARMACEUTICAL COMPOSITION FOR AGOMELATINE BUCAL ADMINISTRATION

Info

Publication number
AR095152A1
AR095152A1 ARP140100376A ARP140100376A AR095152A1 AR 095152 A1 AR095152 A1 AR 095152A1 AR P140100376 A ARP140100376 A AR P140100376A AR P140100376 A ARP140100376 A AR P140100376A AR 095152 A1 AR095152 A1 AR 095152A1
Authority
AR
Argentina
Prior art keywords
agomelatine
pathologies
pharmaceutical composition
excipients
disorders
Prior art date
Application number
ARP140100376A
Other languages
Spanish (es)
Inventor
Genty Patrick
Pean Jean
Manuel - Rioult Fabien
Genissel Patrick
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR095152A1 publication Critical patent/AR095152A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Composición farmacéutica bucal sólida de tipo bicapa, tricapa o con núcleo central destinada a una acción sistémica, que contiene agomelatina o uno de sus hidratos, complejos, co-cristales, formas cristalinas, forma amorfa, sales de adición a un ácido o una base farmacéuticamente aceptable, caracterizada porque está constituida: por una o varias capas periféricas activas «A» que contienen la agomelatina y los excipientes, por una capa placebo «B» que contiene únicamente los excipientes. Reivindicación 14: Composición farmacéutica bucal sólida según una cualquiera de las reivindicaciones 1 a 13, útil para el tratamiento de la depresión mayor, depresiones estacionales, trastorno de ansiedad generalizada, trastorno obsesivo compulsivo, trastornos bipolares, trastornos del sueño, patologías cardiovasculares, patologías del sistema digestivo, insomnios y fatigas debidas a diferencias horarias, trastornos del apetito y obesidad, y el conjunto de las patologías ligadas a un desajuste de los ritmos circadianos.Claim 1: Pharmaceutical solid oral composition of the bilayer, three-layer or central core type intended for a systemic action, containing agomelatine or one of its hydrates, complexes, co-crystals, crystalline forms, amorphous form, acid addition salts or a pharmaceutically acceptable base, characterized in that it is constituted: by one or more active peripheral layers "A" containing agomelatine and excipients, by a placebo layer "B" containing only the excipients. Claim 14: Solid oral pharmaceutical composition according to any one of claims 1 to 13, useful for the treatment of major depression, seasonal depressions, generalized anxiety disorder, obsessive compulsive disorder, bipolar disorders, sleep disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to time differences, appetite disorders and obesity, and all pathologies linked to a mismatch of circadian rhythms.

ARP140100376A 2013-02-08 2014-02-05 SOLID PHARMACEUTICAL COMPOSITION FOR AGOMELATINE BUCAL ADMINISTRATION AR095152A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1351085A FR3001894A1 (en) 2013-02-08 2013-02-08 SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN

Publications (1)

Publication Number Publication Date
AR095152A1 true AR095152A1 (en) 2015-09-30

Family

ID=48289330

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100376A AR095152A1 (en) 2013-02-08 2014-02-05 SOLID PHARMACEUTICAL COMPOSITION FOR AGOMELATINE BUCAL ADMINISTRATION

Country Status (5)

Country Link
AR (1) AR095152A1 (en)
FR (1) FR3001894A1 (en)
TW (1) TW201434495A (en)
UY (1) UY35294A (en)
WO (1) WO2014122405A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020260725A1 (en) * 2019-12-20 2020-12-30 Lts Lohmann Therapie-Systeme Ag Transmucosal therapeutic system containing agomelatine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (en) 1990-02-27 1993-12-31 Adir Cie NOVEL DERIVATIVES WITH NAPHTHALENIC STRUCTURE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
SI1427724T1 (en) 2001-09-19 2006-10-31 Merck Patent Gmbh Novel use of substituted aminomethyl chromans
FR2834890B1 (en) * 2002-01-23 2004-02-27 Servier Lab ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF AGOMELATIN
JP2007517040A (en) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド Melatonin combination therapy to improve sleep quality
FR2866335B1 (en) 2004-02-13 2006-05-26 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN
US7498465B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
FR2889522B1 (en) 2005-08-03 2007-12-28 Servier Lab NOVEL IV CRYSTALLINE FORM OF AGOMELATIN, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2889523B1 (en) 2005-08-03 2007-12-28 Servier Lab NOVEL CRYSTALLINE FORM V OF AGOMELATIN, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2889521B1 (en) 2005-08-03 2007-12-28 Servier Lab NOVEL CRYSTALLINE FORM III OF AGOMELATIN, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2894475B1 (en) * 2005-12-14 2008-05-16 Servier Lab ORODISPERSIBLE PHARMACEUTICAL COMPOSITION FOR OROMUCOSAL OR SUBLINGUAL ADMINISTRATION OF AGOMELATIN
CN101481321B (en) 2009-02-27 2012-04-18 上海医药工业研究院 Agomelatine halogen hydride complex and preparation thereof
CN101585779B (en) 2009-03-10 2014-04-02 上海医药工业研究院 New crystal form of Agomelatine, preparation method and use thereof
WO2011006387A1 (en) 2009-07-11 2011-01-20 浙江华海药业股份有限公司 Process for preparing agomelatine, crystals of agomelatine and preparing process thereof
CN101955440B (en) 2009-07-17 2014-04-09 江苏万特制药有限公司 Crystal form of agomelatine and preparation method thereof
CN102050755B (en) 2009-10-29 2014-11-05 重庆医药工业研究院有限责任公司 Novel agomelatine crystal forms and preparation methods of agomelatine crystal forms
CN102050756A (en) 2009-11-09 2011-05-11 北京利乐生制药科技有限公司 New crystal form of agomelatine and preparation method thereof
CN101781226B (en) 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 Agomelatine and medicine composition thereof
CN101774937B (en) 2010-02-05 2014-01-08 天津市汉康医药生物技术有限公司 N-[2-(7-methoxyl-1-naphthyl)ethyl]acetamide and compound thereof
WO2011111336A1 (en) 2010-03-10 2011-09-15 パナソニック株式会社 Fuel cell system and feeding control system using same
CN102190594A (en) 2010-03-17 2011-09-21 上海医药工业研究院 Agomelatine hydrogen chloride hydrate and preparation method thereof
CN101870662B (en) 2010-05-21 2013-03-20 中山大学 Crystalline Agomelatine solvate and preparation method thereof
WO2012046253A2 (en) 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms
CN102030673B (en) 2010-11-24 2014-04-23 威海迪素制药有限公司 New crystal form of agomelatine and preparation method thereof
CN102078309A (en) * 2011-01-22 2011-06-01 王定豪 Dispersible tablet containing antipsychotic medicines and application thereof
WO2012130837A1 (en) * 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
CN102206864B (en) 2011-04-13 2012-10-03 吉林省博大伟业制药有限公司 Agomelatine monocrystal with agomelatine VI crystal form, agomelatine mixed crystal with the agomelatine VI crystal form and preparation methods
CN102885798B (en) * 2011-07-21 2015-04-22 成都康弘药业集团股份有限公司 Orally disintegrating tablet
CN102503886B (en) 2011-10-11 2013-09-11 中山大学 Agomelatine-isonicotine eutectic crystal and compound and preparation method thereof
CN102432490A (en) 2011-11-02 2012-05-02 江西施美制药有限公司 Agomelatine crystal form D and preparation method thereof

Also Published As

Publication number Publication date
FR3001894A1 (en) 2014-08-15
TW201434495A (en) 2014-09-16
WO2014122405A1 (en) 2014-08-14
UY35294A (en) 2014-08-29

Similar Documents

Publication Publication Date Title
UY35586A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
JP2015523407A5 (en)
UY34974A (en) PIRIDAZINE 1.4 DISPOSED, SAME ANALOGS AND METHODS TO TREAT DISEASES RELATED TO SMN DEFICIENCY
DOP2010000273A (en) SOLID PREPARATION OF ORAL DISINTEGRATION
UY30721A1 (en) IMPROVEMENTS IN AND RELATED TO APPROPRIATE DRIVING MECHANISMS FOR USE IN PHARMACOS DISCHARGE DEVICES
AR075369A1 (en) COMPRESSED FOR COMBINATION THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS.
CL2012002540A1 (en) Agomelatine Hydrochloride Hydrate; crystalline form; Preparation method; pharmaceutical composition; and its use for the treatment of sleep disorders, stress, anxiety, major depression, cardiovascular diseases, among others.
UY37293A (en) PHARMACEUTICAL FORM OF MULTIPLE UNITS UNDERSTANDING A CORE WITH INDIVIDUAL CENTRAL UNITS COVERED BY A MUCO-ADHESIVE MATERIAL, AND AN ENERGY NUCLEUS COATING
JP2016530291A5 (en)
AR076848A1 (en) ANTITUMORAL COMBINATION INCLUDING AVE8062 AND SORAFENIB
BR112015016869A2 (en) dosage form for the administration of an active ingredient for accelerated sleep induction and / or for the treatment of sleep disorders and / or to treat a central nervous system disorder
CL2009000876A1 (en) Crystalline form anhydrous orvepitant maleate; pharmaceutical composition; and its use to treat disorders of the central nervous system, such as depression, anxiety, post-traumatic stress disorders, emesis, and / or sleep disorders.
NI201000181A (en) USE OF DRONEDARONE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRHYTHMIA AND WHO HAVE AN INCREASED CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONE.
AR095152A1 (en) SOLID PHARMACEUTICAL COMPOSITION FOR AGOMELATINE BUCAL ADMINISTRATION
AR065917A1 (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A SUBLINGUAL TABLET THAT INCLUDES A NON-STEROID ANTI-INFLAMMATORY AND AN OPIACEAL ANALGESIC FOR PAIN MANAGEMENT
CO7250447A2 (en) Medication form to release active ingredients
ECSP15033649A (en) A COMBINED MEDICINAL PRODUCT INCLUDING PHENYLEPHRINE AND PARACETAMOL
AR080150A1 (en) USE OF AGOMELATINE FOR THE OBTAINING OF MEDICINES FOR THE TREATMENT OF THE OBSESSIVE COMPULSIVE DISORDER (TOC)
AR077451A1 (en) USE OF BENZIDAMINE IN THE TREATMENT OF P40 DEPENDENT DISEASES
CO2018010142A2 (en) Mesalazine solid formula preparation process
AR094634A1 (en) FORMULATION OF 5-AMINOSALYCLIC ACID CAPSULES
AR081007A1 (en) CHARACTERIZED PHARMACEUTICAL COMBINATION BECAUSE IT INCLUDES IBUPROFEN AND L-ARGININA
RU2015121239A (en) COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING PAIN SYNDROMES
AR095149A1 (en) DRUG THAT INCLUDES PHENYLEFRINE AND PARACETAMOL
CR20150363A (en) COMBINATION OF A MEDICINAL PRODUCT THAT INCLUDES PHENYLEFRINE AND PARACETAMOL

Legal Events

Date Code Title Description
FB Suspension of granting procedure